Advancing Innovative
Oral Medicines
for people with inflammatory and
autoimmune diseases

Selectively modulating
key immune targets

To create differentiated medicines

Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with autoimmune and inflammatory disorders. Our pipeline includes VTX958, an allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, currently completing Phase 1; VTX002, a S1P1 receptor modulator for the treatment of ulcerative colitis, currently in Phase 2; and VTX2735, a peripheral inhibitor of the NLRP3 inflammasome, currently completing Phase 1.


Our approach allows us to streamline the discovery and development process.


Learn about our differentiated clinical-stage candidates and preclinical programs.


We are passionate about advancing novel therapies to improve the lives of patients.

Featured News